What were the primary drivers of Gilead's revenue growth in the first half of 2005?

Gilead's revenue growth in the first half of 2005 was primarily driven by its HIV product franchise, with Viread and the strong performance of newly launched Truvada showing significant increases. Overall product sales grew by 47%, with HIV products experiencing a 54% surge in sales.

What is the status of the Tamiflu agreement with Roche?

Gilead has delivered a notice of termination to Roche for material breach of the Tamiflu Development and License Agreement. This notice, if effective, would result in the termination of Roche's rights to Tamiflu and their reversion to Gilead. Additionally, Gilead's audit revealed a potential underpayment of royalties by Roche amounting to $18.2 million for the period between 2001 and 2003.

How is Gilead preparing for the new stock-based compensation accounting standard (SFAS 123R)?

Gilead expects to adopt SFAS 123R on January 1, 2006. The company is currently evaluating the requirements and option valuation methodologies. While the precise impact is not yet determined, Gilead anticipates that the adoption of SFAS 123R will materially affect its consolidated results of operations and earnings per share, particularly regarding the recognition of stock-based compensation expense and its classification in the statement of cash flows.

What is the company's cash position and liquidity like?

Gilead Sciences ended the quarter with a strong liquidity position. Cash, cash equivalents, and marketable securities totaled $1.79 billion as of June 30, 2005, an increase from $1.25 billion at the end of 2004. This increase was primarily fueled by strong operating cash flows, driven by growth in operating income and effective accounts receivable collections.

GILD 10-Q Quarterly Report Q2 FY2005 — Revenue, Net Income, EPS

Summary

Gilead Sciences, Inc. demonstrated robust financial performance for the six months ended June 30, 2005, with total revenues reaching $925.7 million, a significant increase of 47% compared to the same period in 2004. This growth was primarily driven by a substantial 54% surge in HIV product sales, notably from Viread and the strong uptake of Truvada. The company's net income also saw a considerable rise, reaching $353.1 million for the six-month period. Gilead's balance sheet strengthened, with cash and cash equivalents and marketable securities growing to $1.79 billion. Significant operational developments include progress in collaborative efforts, such as the evaluation of a fixed-dose combination of Truvada and Sustiva with Bristol-Myers Squibb, and the initiation of a Phase I/II clinical trial for a novel HIV integrase inhibitor. However, the company is also navigating complex legal and contractual situations, including a notice of termination to Roche regarding the Tamiflu agreement and an ongoing audit for potential royalty underpayments. Furthermore, Gilead is preparing for the adoption of new accounting standards (SFAS 123R) which is expected to materially impact its reported results.

Key Highlights

1Total revenues for the six months ended June 30, 2005, increased by 47% to $925.7 million compared to the prior year period.
2Product sales grew by 47% to $848.7 million for the six months ended June 30, 2005, largely driven by a 54% increase in HIV product sales.
3Truvada, launched in the prior year, showed strong uptake, contributing significantly to the HIV product sales growth.
4Net income for the six months ended June 30, 2005, was $353.1 million, an increase from $225.9 million in the comparable period of 2004.
5Cash, cash equivalents, and marketable securities increased to $1.79 billion as of June 30, 2005, indicating strong liquidity.
6Gilead issued a notice of termination to Roche for material breach of the Tamiflu Development and License Agreement and identified a potential underpayment of royalties by Roche.
7The company is preparing for the adoption of SFAS 123R (Share-Based Payment), which is expected to have a material impact on its financial statements.

GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended Jun 30, 2005

Summary

Key Highlights

Frequently Asked Questions